Gilead Sciences garnered investor and analyst focus after the U.S. FDA approval of Yeztugo, or lenacapavir, the company’s ...

The FDA has approved Yeztugo, the first long-acting injectable PrEP shot, which could significantly impact HIV prevention efforts globally and locally.